| 7.81 -0.05 (-0.64%) | 05-29 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 9.52 | 1-year : | 10.1 |
| Resists | First : | 8.15 | Second : | 8.64 |
| Pivot price | 7.97 |
|||
| Supports | First : | 7.34 | Second : | 6.11 |
| MAs | MA(5) : | 7.88 |
MA(20) : | 8.04 |
| MA(100) : | 8.21  |
MA(250) : | 7.42 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 41 |
D(3) : | 43.1 |
| RSI | RSI(14): 42.8 |
|||
| 52-week | High : | 9.07 | Low : | 6.3 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ KMDA ] has closed above bottom band by 35.1%. Bollinger Bands are 20.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 7.86 - 7.91 | 7.91 - 7.94 |
| Low: | 7.69 - 7.75 | 7.75 - 7.79 |
| Close: | 7.73 - 7.81 | 7.81 - 7.88 |
Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis ; and ELIGARD for prostate cancer. The company markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.
Fri, 29 May 2026
Kamada Ltd stock (IL0010952647): shares stabilize after recent results as investors eye valuation me - AD HOC NEWS
Tue, 26 May 2026
KMDA News | KAMADA LTD (NASDAQ:KMDA) - ChartMill
Thu, 14 May 2026
Kamada Ltd. (NASDAQ:KMDA) Q1 2026 Earnings Call Transcript - Insider Monkey
Wed, 13 May 2026
Kamada: Q1 Earnings Snapshot - WKYC
Wed, 13 May 2026
Kamada (KMDA) Misses Q1 Earnings and Revenue Estimates - Yahoo Finance
Wed, 13 May 2026
Rare-disease drug maker Kamada sees demand rising, sticks to 2026 targets - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 58 (M) |
| Shares Float | 11 (M) |
| Held by Insiders | 7.1 (%) |
| Held by Institutions | 48.6 (%) |
| Shares Short | 102 (K) |
| Shares Short P.Month | 163 (K) |
| EPS | 0.34 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.65 |
| Profit Margin | 11.2 % |
| Operating Margin | 15.3 % |
| Return on Assets (ttm) | 4.1 % |
| Return on Equity (ttm) | 7.9 % |
| Qtrly Rev. Growth | 2.7 % |
| Gross Profit (p.s.) | 1.29 |
| Sales Per Share | 3.14 |
| EBITDA (p.s.) | 0.67 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 26 (M) |
| Levered Free Cash Flow | 10 (M) |
| PE Ratio | 22.31 |
| PEG Ratio | 0.5 |
| Price to Book value | 1.67 |
| Price to Sales | 2.47 |
| Price to Cash Flow | 17.52 |
| Dividend | 0.25 |
| Forward Dividend | 0 |
| Dividend Yield | 3.2% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|